UniQure Expects To Resolve FDA Clinical Hold Within Three Months
The gene therapy EtranaDez for hemophilia B placed on clinical hold after a patient was diagnosed with liver cancer, but UniQure points to that patient’s extensive history of liver disease.
You may also be interested in...
Unveiling its latest data, UniQure is tipped to avoid the knockback which affected BioMarin’s hemophilia A gene therapy, with a filing expected in the second half of 2021.
While M&A-hungry investors were disappointed in no sale, uniQure now aims to pivot toward Huntington’s – and sees Zolgensma as an example to follow.
Observers have been expecting uniQure to be sold off as a whole but the Netherlands-based firm has chosen to sell just one asset - EtranaDez - and focus on advancing its Huntington’s disease gene therapy.